Pyng Medical Corp. Pursuing Regulatory Registration In China
Vancouver, BC - Pyng Medical Corp. is pursuing Chinese FDA (SFDA) regulatory registration in support of launching the FAST1™ Intraosseous Infusion System into The People’s Republic of China. Pyng has retained Beijing Jyton & Kannel Medical Technology Co., Ltd. as its exclusive regulatory representative in China.
“The opportunity for FAST1™ in China is as enormous as the country itself. With advancements in Chinese health care, the world’s largest standing military, and a vast network of emergency medical service needs, Pyng is perfectly positioned to penetrate this huge and growing market with our innovative FAST1™ Intraosseous Infusion System,” said David Christie, President and Chief Executive Officer of Pyng.
Beijing Jyton & Kannel is an experienced Chinese company with a track record of successfully registering medical devices for its overseas clients. They will be working closely with Pyng and Pyng’s Asian representative, Business Asia Consultants.
About Pyng Medical Corp.
Pyng Medical Corp. is a world leader in intraosseous infusion with its proprietary award-winning FAST1™ Intraosseous Infusion System, the only device able to provide rapid sternal access and delivery of life saving fluids and drugs to the heart of critically injured patients within seconds. The FAST1™ is used extensively by the U.S. Department of Defense and by Emergency Medical Services around the globe.
For More Information
David Christie
Pyng Medical Corp.
(604) 303-7964
www.pyng.com
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.